• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Voynick Eileen J. was granted 6,742 shares, increasing direct ownership by 79% to 15,226 units (SEC Form 4)

    6/3/25 4:10:52 PM ET
    $OMCL
    Computer Manufacturing
    Technology
    Get the next $OMCL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Voynick Eileen J.

    (Last) (First) (Middle)
    OMNICELL, INC
    4220 NORTH FREEWAY

    (Street)
    FORT WORTH TX 76137

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    OMNICELL, INC. [ OMCL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/01/2025 A 6,742(1) A $0 15,226 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board Member pursuant to the Issuer's Board of Directors Compensation Plan. Shares shall vest in full on the one-year anniversary of the grant date.
    /s/ Vijay Biligiri Attorney in Fact for Eileen J. Voynick 06/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OMCL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMCL

    DatePrice TargetRatingAnalyst
    5/14/2025$35.00Equal Weight → Overweight
    Wells Fargo
    10/31/2024$44.00 → $57.00Buy → Neutral
    BofA Securities
    8/2/2024$26.00 → $39.00Underweight → Equal Weight
    Barclays
    1/3/2024$33.00Underweight
    Barclays
    11/3/2023$39.00 → $28.00Underweight → Equal Weight
    Wells Fargo
    11/3/2023Buy → Neutral
    BTIG Research
    11/3/2023$70.00 → $39.00Neutral → Overweight
    Piper Sandler
    10/11/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $OMCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Omnicell upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Omnicell from Equal Weight to Overweight and set a new price target of $35.00

    5/14/25 8:50:33 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell downgraded by BofA Securities with a new price target

    BofA Securities downgraded Omnicell from Buy to Neutral and set a new price target of $57.00 from $44.00 previously

    10/31/24 7:49:39 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell upgraded by Barclays with a new price target

    Barclays upgraded Omnicell from Underweight to Equal Weight and set a new price target of $39.00 from $26.00 previously

    8/2/24 7:36:45 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Omnicell Announces Second Quarter 2025 Results

    Omnicell delivers strong second quarter financial results Results exceed previously issued second quarter 2025 guidance for revenues, non-GAAP EBITDA and non-GAAP EPS Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its second quarter ended June 30, 2025. "We are pleased to deliver another quarter of strong financial performance, with total revenues, non-GAAP EPS and non-GAAP EBITDA for second quarter 2025 all exceeding the upper end of our previously provided gu

    7/31/25 6:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell to Release Second Quarter 2025 Financial Results on July 31, 2025

    Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the second quarter 2025, before market open on Thursday, July 31, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 3131192. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. A

    7/14/25 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program

    Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced updates to its second quarter and full year 2025 outlook for Non-GAAP EBITDA and Non-GAAP earnings per share, and the authorization of a new $75 million stock repurchase program. "The Administration's recent announcement of a reduction in tariff rates on imports from China has compelled us to update our second quarter and full-year 2025 outlook to reflect the expected diminished impact on our supply chain and anticipated improved profitability," stated Randall Lipps, chairman, president, chief executive officer,

    5/22/25 8:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    3/18/25 4:13:27 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    SEC Filings

    View All

    SEC Form 10-Q filed by Omnicell Inc.

    10-Q - OMNICELL, INC. (0000926326) (Filer)

    8/6/25 4:06:36 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OMNICELL, INC. (0000926326) (Filer)

    7/31/25 6:33:32 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form S-8 filed by Omnicell Inc.

    S-8 - OMNICELL, INC. (0000926326) (Filer)

    6/18/25 4:04:58 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Leadership Updates

    Live Leadership Updates

    View All

    Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer

    The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925324631/en/Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024

    9/25/24 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer

    FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to me

    4/22/24 4:05:00 PM ET
    $CLOV
    $OMCL
    Medical Specialities
    Health Care
    Computer Manufacturing
    Technology

    Omnicell Elects Eileen Voynick to Board of Directors

    Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e

    1/11/24 4:00:00 PM ET
    $MDRX
    $OMCL
    $CDK
    EDP Services
    Technology
    Computer Manufacturing
    Retail: Computer Software & Peripheral Equipment

    $OMCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    12/11/23 9:36:42 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    9/11/23 1:33:44 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    2/9/23 11:27:45 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Financials

    Live finance-specific insights

    View All

    Omnicell Announces Second Quarter 2025 Results

    Omnicell delivers strong second quarter financial results Results exceed previously issued second quarter 2025 guidance for revenues, non-GAAP EBITDA and non-GAAP EPS Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its second quarter ended June 30, 2025. "We are pleased to deliver another quarter of strong financial performance, with total revenues, non-GAAP EPS and non-GAAP EBITDA for second quarter 2025 all exceeding the upper end of our previously provided gu

    7/31/25 6:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell to Release Second Quarter 2025 Financial Results on July 31, 2025

    Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the second quarter 2025, before market open on Thursday, July 31, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 3131192. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. A

    7/14/25 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Announces First Quarter 2025 Results

    Omnicell delivers solid first quarter financial results Results exceed previously issued first quarter 2025 guidance for total revenues and non-GAAP EPS Updates full year 2025 non-GAAP EBITDA and non-GAAP EPS guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its first quarter ended March 31, 2025. "We delivered strong financial results for the first quarter of 2025, exceeding our previously provided guidance ranges for both revenue and earnings, which we believe reflects customers embracing the industry-defined vision of the Autonomous P

    5/6/25 6:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, PRESIDENT AND CEO Lipps Randall A covered exercise/tax liability with 1,146 shares, decreasing direct ownership by 0.28% to 403,523 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    6/17/25 5:27:57 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J covered exercise/tax liability with 332 shares, decreasing direct ownership by 0.28% to 117,126 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    6/17/25 5:27:11 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Director Parrish Mark W was granted 6,828 shares, increasing direct ownership by 12% to 65,255 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    6/3/25 4:12:37 PM ET
    $OMCL
    Computer Manufacturing
    Technology